Afaf E. Osman
( out of 31 reviews )

Afaf E. Osman, MD

Languages spoken: Arabic, English

  • Dr. Osman's clinical interest is in myeloid malignancies. Her research interest is in studying clonal hematopoiesis as a precursor condition to myeloid malignancies.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 31 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    February 05, 2024
    HUNTSMAN CANCER CENTER

    She is kind and professional.

    January 30, 2024
    HUNTSMAN CANCER CENTER

    She is smart, patient and kind.

    January 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Osman is very caring. She manages my disease, symptoms, medications, and response to treatment while keeping me in the loop and involving me in my care. I feel she has my best interest and provides wonderful care!

    December 17, 2023
    HUNTSMAN CANCER CENTER

    Dr. Osman really listens and answers all my questions

    November 30, 2023
    HUNTSMAN CANCER CENTER

    She is professional, a very good listener and smart.

    November 15, 2023
    HUNTSMAN CANCER CENTER

    Dr. Osman is the perfect provider for me. She sits down and explains my test results, medications, options, and develops a plan with me for my best health. I like that Dr. Osman and her staff are caring and helpful!

    October 30, 2023
    HUNTSMAN CANCER CENTER

    She is our hero. She cares and is professional.

    October 15, 2023
    HUNTSMAN CANCER CENTER

    Dr. Osman is thoughtful and caring. She understands my health concerns and works with me for the best treatment for my blood disease. Absolutely a wonderful provider!

    October 08, 2023
    HUNTSMAN CANCER CENTER

    Attentive to my needs & questions

    See More Patient Comments

  • Dr. Osman's clinical interest is in myeloid malignancies. Her research interest is in studying clonal hematopoiesis as a precursor condition to myeloid malignancies.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Leukemia - University of Chicago Research Fellow
    Hematology & Oncology - University of Chicago Clinical Fellow
    Residency Internal Medicine - Johns Hopkins Hospital Resident
    Medicine - Weill Cornell Medical College in Qatar M.D.
    Certification Premedical Program - Weill Cornell Medical College in Qatar Pre Med

    Selected Publications

    Journal Article

    1. Osman AEG, Rets A, Patel AB (2024). KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia. Leuk Res, 138, 107466. (Read full article)
    2. Wang C, Ma A, Li Y, McNutt ME, Zhang S, Zhu J, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q, exORIEN Consortium (2023). A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset. Cancer Res Commun, 4(2), 293-302. (Read full article)
    3. Wheeler CE, Coleman SS 4th, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC (2023). The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. (Read full article)
    4. Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS 4th, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q (2023). A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset. (Read full article)
    5. Osman AEG, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai M, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley LA (2022). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv, 7(9), 1910-1914. (Read full article)
    6. Osman A, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai MJ, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley LA (2022). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv, 7(9), 1910-1914. (Read full article)
    7. Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Perla G, Park L, Larson RA, Liao JK (2022). Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol, 4(3), 371-383. (Read full article)
    8. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064. (Read full article)
    9. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199. (Read full article)
    10. Feurstein S, Adegunsoye A, Mojsilovic D, Vij R, DePersia AHW, Rajagopal PS, Osman A, Collins RH, Kim RH, Gore SD, Greenberg P, Godley LA, Li Z, Del Gaudio D, Subramanian HP, Das S, Walsh T, Gulsuner S, Segal JP, Husain AN, Gurbuxani S, King MC, Strek ME and Churpek JE (2020). Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv, 4(19), 4873-4886.
    11. Osman A, Gocke CD, Gladstone DE (2016). Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. Clin Lymphoma Myeloma Leuk, 17(2), 97-99. (Read full article)
    12. Osman A, et al (2014). Sudden Worsening of DRESS Syndrome on Tapering Steroid Dose with Dramatic Improvement on N-acetylcysteine and Steroid Dose Escalation. 6(2), 101-10.

    Review

    1. Liu J, Osman AEG, Bolton K, Godley LA (2023). Germline predisposition to clonal hematopoiesis. [Review]. Leuk Res, 132, 107344. (Read full article)
    2. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. [Review]. Clin Neurol Neurosurg, 212, 107064. (Read full article)
    3. Osman AEWG (2021). When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)? [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 399-404. (Read full article)
    4. Osman AEG, Deininger MW (2021). Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. [Review]. Blood Rev, 49, 100825. (Read full article)
    5. Osman A, Patel JL (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. [Review]. Clin Chem, 67(8), 1062-1070. (Read full article)
    6. Osman AEG, Luke JJ (2019). The Impact of the Fecal Microbiome on Cancer Immunotherapy. [Review]. BioDrugs, 33(1), 1-7. (Read full article)
    7. Akpan IJ, Osman AEG, Drazer MW, Godley LA (2018). Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. [Review]. Curr Hematol Malig Rep, 13(6), 426-434. (Read full article)
    8. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA (2018). Treatment of Acute Promyelocytic Leukemia in Adults. [Review]. J Oncol Pract, 14(11), 649-657. (Read full article)

    Case Report

    1. Osman A, Galiatsatos P, Bose S, Danoff S (2017). Rheumatoid arthritis causing diffuse alveolar haemorrhage: a novel therapeutic approach. BMJ Case Rep, 2017. (Read full article)

    Abstract

    1. Osman AYu B, Glavin N, Polonsky T, Liao J, Larson RA (2018). ABL Tyrosine Kinase Inhibitors (TKIs) are Associated with Increased Rho-Associated Kinase (ROCK) Activity that May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Poster session: 632 Chronic Myeloid Leukemia: Therapy, American Society of Hematology 60th Annual Meeting, San Diego, CA [Abstract]. 132(Suppl 1), 1739.
    2. Osman AGaliatsatos PBose S (2017). Diffuse Alveolar Hemorrhage as a Rare Manifestation of Rheumatoid Arthritis. Poster session presented at the Autoimmune Lung Disease: Case Reports Thematic Poster Session. American Thoracic Society International Conference, Washington, DC [Abstract]. 195, A1460.

    Other

    1. Osman AEG, Luke JJ (2019). The Gut Microbiome and Cancer Immunotherapy. (4(8), pp. 14, 15).

  • News & Podcasts